PPARG and breast carcinoma: Similarly, in a mouse model of breast cancer, the combination of celecoxib and the PPAR‐γ agonist N‐(9‐fluorenyl‐methyloxycarbonyl)‐l‐leucine (F‐L‐Leu) significantly delayed the tumour progression.112